Neocarzinostatin
WikiDoc Resources for Neocarzinostatin |
Articles |
---|
Most recent articles on Neocarzinostatin Most cited articles on Neocarzinostatin |
Media |
Powerpoint slides on Neocarzinostatin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Neocarzinostatin at Clinical Trials.gov Trial results on Neocarzinostatin Clinical Trials on Neocarzinostatin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Neocarzinostatin NICE Guidance on Neocarzinostatin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Neocarzinostatin Discussion groups on Neocarzinostatin Patient Handouts on Neocarzinostatin Directions to Hospitals Treating Neocarzinostatin Risk calculators and risk factors for Neocarzinostatin
|
Healthcare Provider Resources |
Causes & Risk Factors for Neocarzinostatin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Neocarzinostatin is a macromolecular chromoprotein antibiotic with anti-tumoral activity secreted by Streptomyces macromomyceticus.
It consists of a labile chromophore (bicyclic dienediyne structure, Mr = 659) that is tightly and non-covalently bound to an apoprotein (113 amino acids) with high affinity (Kd ~ 10-10M). The chromophore is a very potent DNA-damaging agent; it is very labile and the role of the apoprotein is to protect it and release it to the target DNA. Other members of the Neocarzinostatin group of antibiotics are macromomycin, actinoxanthin, kedarcidin and maduropeptin.